BioMarin’s (BMRN) Phase 3 Trial of BMN 401 for ENPP1 Deficiency Meets One Co-Primary Endpoint

BioMarin's Phase 3 trial of BMN 401 for ENPP1 deficiency meets one co-primary endpoint.

Key Points

• BMN 401 shows promise for ENPP1 deficiency.
• Trial meets one of two co-primary endpoints.
• Further results expected to guide future development.